ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1861

Modelling the Interaction Between Disease Microenvironment and Mesenchymal Cells in Systemic Sclerosis

Zeinab Taki1, Bahja Ahmed Abdi2, Henrique Rosario3, Sara Zafar4, Amy Hart3, Shiwen Xu5, Christopher Denton6, David Abraham6 and Richard J. Stratton7, 1Department of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 2Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, 3Centre of Rheumatology and Connective Tissue disease, University College London, London, United Kingdom, 4Centre of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 5Division of Medicine, ​Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, 6Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 7Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: mesenchymal stem cells and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Sclerosis (SSc) has complex aetiology with many potential driving forces, one of which is the microenvironment in lesional skin, in which resident mesenchymal stem cells (MSCs), are exposed to aberrantly expressed growth factors and cytokines, and excessively stiffened and abundant extracellular matrix. We hypothesise that MScs are persistently activated within this microenvironment contributing to chronic aberrant tissue repair and fibrosis. The effects of skin blister fluid (BF) and IL-31, the maximally induced cytokine in SSc BF, were studied in models of interaction between the disease microenvironment and MSCs. MSCs were studied in situ using amitotic nuclear division as a marker of their activation.

Methods: Staining of tissue spreads for metakaryotic nuclear divisions was used as a method to identify MSCs in SSc tissues. SSc BF sampled from forearm skin, as well as control BF (each diluted 1:125 in 0.2% DMEM) and IL-31, were studied as possible agonists in scratch wound assays and Western blots for SSc associated proteins. MSCs derived from both adipose and skin biopsy tissue were induced to differentiate into osteoblasts on soft and stiff extracellular matrix representations. Levels of pro-fibrotic factors were measured by qPCR in MSCs exposed to microenvironment representations.

Results: Metakaryotic nuclear divisions were observed in cells associated with fibrillar collagen in the deep dermal layer of SSc skin. SSc BF enhanced migration of MSCs compared with control BF, (~1 and ~0.7 mm2 respectively p=0.231) and induced αSMA expression in MSCs ~ 3 times more than media only and ~ 1.5 times more than control BF. Collagen I and CTGF expression were also induced in MSCs by SSc BF. In addition, IL-31 enhanced migration of SSc and control dermal fibroblasts in the scratch wound assay (1.3mm2 SEM=0.08 and 0.45mm2 SEM= 0.07 in 0.2% DMEM and 50ng/ml IL-31 respectively at 20 hours, p=0.0001), inhibited by Wortmannin and U0126 (1.4mm2 and 1.3mm2 respectively, p=0.0001). The same was seen with MSCs, by 24 hours the area of the scratch in IL-31 treated wells was 0.9mm2 compared to 1.5mm2 for Wortmannin treatment (p=0.027). IL-31 did not fully reproduce the protein and migratory effects of blister fluid on MSCs. IL-31 had no effect on Collagen I expression (relative density of 0.7 vs 1.0 and 2.4 for 0.2% DMEM and SSc BF respectively). Matrix stiffness enhanced osteogenic differentiation of MSCs, this effect was enhanced further with IL-31 and TGFβ but abolished when treated with CCG1423 (an inhibitor of the matrix sensing protein MRTFA). Stiff matrices also elevated expression of a-SMA and Collagen I mRNA.

Conclusion: Proliferating metakaryotic cells were found to be present in the deep dermis of SSc patients and they may represent activated stem cells. SSc patients BF and SSc associated cytokine IL-31 enhanced pro-fibrotic differentiation of MSCs. Our findings suggest that MSCs may be important in SSc pathogenesis and that factors within the dermal interstitial fluid generate a microenvironment inducing them to create or induce excessive pro-fibrotic cells.


Disclosure: Z. Taki, None; B. Ahmed Abdi, None; H. Rosario, None; S. Zafar, None; A. Hart, None; S. Xu, None; C. Denton, GSK, Celgene, Actelion, Bayer, Sanofi, Roche-Genentech, Inventiva, 5,CSL Behring, GSK, Actelion, Roche-Genentech, Inventiva, 2; D. Abraham, None; R. J. Stratton, None.

To cite this abstract in AMA style:

Taki Z, Ahmed Abdi B, Rosario H, Zafar S, Hart A, Xu S, Denton C, Abraham D, Stratton RJ. Modelling the Interaction Between Disease Microenvironment and Mesenchymal Cells in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/modelling-the-interaction-between-disease-microenvironment-and-mesenchymal-cells-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modelling-the-interaction-between-disease-microenvironment-and-mesenchymal-cells-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology